when will hims stop selling semaglutide will - HimsGLP-1 reviews Hims When Will Hims Stop Selling Semaglutide? An In-Depth Look at the Company's Recent Decisions

Himsand Hers lawsuit The question of when will Hims stop selling semaglutide has become a focal point for consumers interested in weight management solutionsHims & Hers Stops Selling Compounded Weight-Loss Pill .... In recent times, Hims & Hers Health Inc. (NYSE:HIMS) has made significant shifts in its offerings, particularly concerning compounded semaglutide and its association with the popular weight-loss drug Wegovy2026年2月7日—The compounded medicine thatHimshad planned tosellwasn't approved and had not gone through trials to demonstrate that itwouldbe effective.. Understanding these changes requires a look at regulatory actions, legal challenges, and the company's strategic responses.

Hims & Hers initially launched a compounded version of semaglutide, marketed as a more accessible alternative. This move came at a time when branded semaglutide products faced shortages.Hims & Hers Stops Selling Semaglutide After FDA Review For example, the U.SHims & Hers Stops Selling Compounded Semaglutide Pill .... Food and Drug Administration (FDA) had declared semaglutide shortages, which created a perceived loophole for companies to offer compounded versions. However, this landscape has rapidly evolved.

Hims announced on Feb. 7, 2026, that it would stop selling the compounded semaglutide pill. This decision was a direct response to pressure from UNovo Nordisk Lawsuit Tests Hims And Hers Weight Loss ....SHims: Why The Semaglutide Shortage May End Imminently. regulators and the escalating scrutiny surrounding these compounded medications2026年2月7日—Hims& Hers has abandoned plans tosella compounded version of Novo Nordisk's weight loss pill following backlash from U.S. regulators and the .... The company was facing significant backlash, with the FDA warning companies about illegally selling unapproved drugs containing semaglutide, tirzepatide, or retatrutide that were falsely labeled. This prompted Hims to pull its "knock-off Wegovy" launch shortly thereafter.Hims & Hers Expands Personalized Weight Loss Portfolio ...

Further complicating the situation, Novo Nordisk, the manufacturer of Wegovy and Ozempic, has taken legal action. Novo Nordisk sued Hims & Hers over alleged patent infringement related to its compounded weight-loss drugs.2026年2月9日—Marty Makary tweeted his concern after the market's close on Thursday whileHims' shares fell. "No oneshouldbe mass-compounding orselling... This lawsuit escalated the dispute between the two entities.Hims & Hers pulls copycat weight-loss pill after legal threats One of the key dates in this legal battle is February 18, 2025, marking a period after which enforcement against compounding outside of a shortage might be more stringent.

The narrative around Hims & Hers and semaglutide is dynamic.2026年2月8日—Hims& Hers has quickly backtracked on plans tosella compounded version of Novo Nordisk's oral Wegovy (semaglutide) after the FDA ... Initially, Hims had planned to sell a compounded medicine that, according to reports, had not been approved and had not undergone trials to demonstrate its effectiveness. This lack of FDA approval for the compounded version was a significant concern for regulators.Hims: Why The Semaglutide Shortage May End Imminently The company's plan for a commercial launch of a compounded semaglutide tablet was advertised on February 5, 20262025年6月23日—Hims & Hers stock plunged around 30% on Mondayafter drugmaker Novo Nordisk abruptly ended a month-long collaboration to make its weight loss drug Wegovy .... However, Hims & Hers has since clarified its position.Hims& Hers Expands Personalized Weight Loss Portfolio with Access to CompoundedSemaglutidePills Starting at /Month*. February 5, 2026. SAN ...

In the aftermath of these developments, Hims & Hers announced it will stop offering access to the compounded semaglutide pillHims& Hers Expands Personalized Weight Loss Portfolio with Access to CompoundedSemaglutidePills Starting at /Month*. February 5, 2026. SAN .... This move was a significant backtrack, occurring just approximately two days after the initial announcement of the semaglutide pill launch. The company stated it would stop selling the pills, a decision reportedly made after the U.SFDA and Novo Nordisk Warn of GLP-1 Telehealth .... FDA review and subsequent threats of decisive action against illegal copycat drugs.

For clarity on the availability of semaglutide through Hims & Hers, it's important to note that prior to these recent changes, the company currently sells compounded semaglutide injections online.2026年2月6日—San Francisco-basedHimssaid itwilllaunch its compounded pill at for the first month, as part of an introductory offer for new ... However, there has been no official announcement regarding whether this specific offering will continue.

The FDA declared the semaglutide shortage resolved in February 2025, which effectively closed a legal loophole that had allowed companies like Hims to sell compounded versions. Consequently, Hims & Hers will no longer be able to sell compounded semaglutide as of May 22, 2025. The company themselves indicated that they will stop offering their current iteration of compounded semaglutide after the first quarter of 2025.

In summary, the question of when will Hims stop selling semaglutide is answered by a series of events culminating in the company's decision to cease offering compounded semaglutide pillsNovo Nordisk, Hims & Hers partner to sell Wegovy. This cessation is directly tied to regulatory pressure from the FDA, Novo Nordisk’s legal actions for patent infringement, and the eventual resolution of the semaglutide shortage. While Hims & Hers has historically provided access to compounded semaglutide injections online, their future offerings in this specific drug class are subject to ongoing regulatory and legal reviews.2026年2月4日—FDA has warned companies that have illegally sold unapproved drugs containingsemaglutide, tirzepatide or retatrutide that are falsely labeled “for research ... The Hims & Hers stock plunged around 30% on Monday following these developments, underscoring the market's reaction to the company's shifting strategy in the weight-loss drug sector. Consumers seeking information on Hims compounded semaglutide should consult the company's official channels for the most up-to-date information.